|The Arylalkamine N-Acetyltransferase n/a (Catalog #MBS617001) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The Arylalkamine N-Acetyltransferase (AANAT) reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s Arylalkamine N-Acetyltransferase can be used in a range of immunoassay formats including, but not limited to, ELISA (EL/EIA). Researchers should empirically determine the suitability of the Arylalkamine N-Acetyltransferase n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Arylalkylamine N-Acetyltransferase (AANAT) is the penultimate enzyme is melatonin synthesis. Hormonal melatonin has been implicated in sleep and circadian clock function, and acts as ìthe hormone of the night.î Large changes in the abundance of AANAT are believed to be responsible for the large day/night rhythms in melatonin synthesis in the pineal gland and retina (1,2). Most research shows that AANAT activity is regulated by controlling the steady-state levels of the protein. Recent research, however, suggests that another mechanism may also play a role in controlling melatonin production without altering AANAT protein and activity. This mechanism may explain the sudden physiological increase in circulating melatonin observed at the onset of the dark period in humans (3).
Immunogen: Human AANAT. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing Arylalkamine N-Acetyltransferase are readily searchable from our website. Different antibodies against the same target such as Arylalkamine N-Acetyltransferase may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.